2D-QSAR Modeling of Quinazoline Derivatives as EGFR Inhibitors for Colorectal Cancer

Abstract

Background: Globally, colorectal cancer represents one of the most common types of cancer, along with being one of the top 10 causes of cancer-related deaths. Epidermal Growth Factor Receptors (EGFRs) are a major target for colorectal cancer, and quinazoline derivatives have shown anticancer activity as EGFR inhibitors.

Purpose: The objective of this research was the development of a two-dimensional quantitative structure–activity relationship model (2D-QSAR); that is, to develop a simple way to identify the structural components that help predict a potent compound with the highest predicted activity among the series of quinazoline derivatives for EGFR inhibitors for colorectal cancer.

Methods: A dataset of 21 quinazoline derivatives was collected from the literature, molecular descriptors were calculated, and Partial Least Squares (PLS) regression was used to develop statistically significant QSAR models. Generated and validated using internal and external validation parameters.

Results: Model-1 (RANDOM_70_30_SFB_PLS_TRIALS_2) showed the best statistical performance with r² = 0.6538, q² = 0.5314, pred-r² = 0.6940, and an F-test value of 22.6638. The descriptors SsssNcount and SaaCHE-index were identified as significant contributors to EGFR inhibitory activity, indicating that tertiary nitrogen count and charge distribution play crucial roles in determining biological potency.

Conclusion: The developed 2D-QSAR model identified a potent compound with the highest predicted biological activity as an EGFR inhibitor for colorectal cancer.

  • Page Number : 133-141
  • Published Date : 2026-08-13
  • Keywords
    Quantitative structure-activity relationship, Partial least squares, Cross-validated coefficient, Quinazoline, Colon cancer
  • DOI Number
    10.15415/jptrm.2025.132008
  • Authors
    Rishab Pathak, Mayank Garhewal, Shani Yadav, Jyoti Prakash Panda, Achal Mishra, Ayush Tiwari, Avantika Agrawal, Shekhar Verma, and Yogesh Vaishnav

References

  • Alsfouk, A. A., Channar, P. A., Bilal, M. S., Ejaz, S. A., & Kim, S. J. (2026). Designing of promising VEGFR‐2 inhibitors by using QSAR modeling, molecular docking, and molecular dynamic simulation: Implications toward the treatment of cancer. Journal of Chemistry, 2026(1), 9405335. https://doi.org/10.1155/joch/9405335
  • Bentharavithana, J., Islam, T., & Xu, B. (2025). Medicinal mushrooms in colon cancer therapy: Mechanisms of action of bioactive compounds and therapeutic potential. International Journal of Molecular Sciences, 26(11), 5304. https://doi.org/10.3390/ijms26115304
  • Dhuguru, J., & Ghoneim, O. A. (2022). Quinazoline based HDAC dual inhibitors as potential anti-cancer agents. Molecules, 27(7), 2294. https://doi.org/10.3390/molecules27072294
  • Mansouri, M. M., Emami, L., Rezaei, Z., & Khabnadideh, S. (2025). Design, synthesis, biological assessments and computational studies of 3-substituted phenyl quinazolinone derivatives as promising anti-cancer agents. BMC Chemistry, 19(1), 125. https://doi.org/10.1186/s13065-025-01492-4
  • Mohamed, A. M., Abou-Ghadir, O. M. F., Mostafa, Y. A., Almarhoon, Z. M., Bräse, S., & Youssif, B. G. M. (2024). Design, synthesis, and antiproliferative activity of new 1,2,3-triazole/quinazoline-4-one hybrids as dual EGFR/BRAF V600E inhibitors. RSC Advances, 14(52), 38403–38415. https://doi.org/10.1039/D4RA06694D
  • Panda, J. P., Garhewal, M., Jain, S. K., Yadav, S., Mishra, A., Pathak, R., Tiwari, A., Verma, S., & Vaishnav, Y (2026). Designing novel indole-based anticancer drugs: Insights from 3D-QSAR and molecular field analysis.
  • Pravin, S., & Sudhir, A. (2018). Integration of 3D printing with dosage forms: A new perspective for modern healthcare. Biomedicine & Pharmacotherapy, 107, 146–154. https://doi.org/10.1016/j.biopha.2018.07.167
  • Radzikowska-Bűchner, E., Radej, S., Niezabitowska, E., Sitarz, R., & Szewc, M. (2025). Potential of using new indole- and benzimidazo[1,2-C]quinazolines in anticancer therapy based on mesenchymal stem cells. Cancer Management and Research, 17, 1087–1097. https://doi.org/10.2147/CMAR.S516593
  • Raut, V. V., Bhandari, S. V., Patil, S. M., & Sarkate, A. P. (2023). A rational approach to anticancer drug design: 2D and 3D-QSAR, molecular docking and prediction of ADME properties using silico studies of thymidine phosphorylase inhibitors. Letters in Drug Design & Discovery, 20(2), 153–166. https://doi.org/10.2174/1570180819666220215115633
  • Ryad, N., Elmaaty, A. A., M Ibrahim, I., Ahmed Maghrabi, A. H., Yahya Alahdal, M. A., Saleem, R. M., Zaki, I., & Ghany, L. M. A. A. (2024). Harnessing molecular hybridization approach to discover novel quinoline EGFR-TK inhibitors for cancer treatment. Future Medicinal Chemistry, 16(11), 1087–1107. https://doi.org/10.1080/17568919.2024.2342201
  • Vaishnav, Y., Thakur, A., Kaur, C. D., Verma, S., Mishra, A., Jain, S. K., & Ghode, P. (2018). QSAR analysis of some N, N-diphenyl urea derivatives as CCR5 receptor antagonist. Research Journal of Pharmacy and Technology, 11(9), 3802. https://doi.org/10.5958/0974-360X.2018.00697.2
  • Vaishnav, Y., Yadav, S., Jain, S. K., Panda, J. P., Mishra, A., Garhewal, M., Pathak, R., & Verma, S. (2026). 2D-QSAR analysis and molecular descriptor insights for designing potent anticancer pyrazolopyrimidine derivatives. RASAYAN Journal of Chemistry, 19(02), 921–931. https://doi.org/10.31788/RJC.2026.1929617
  • Wang, R., Han, X., Zhu, L., Wang, W., Gu, Y., Zhang, W., & Guo, W. (2025). Combination of fruquintinib with venetoclax for the treatment of colorectal cancer. Oncology Research, 33(1), 225–234. https://doi.org/10.32604/or.2024.050047
  • Zhang, J., Liu, Q., Zhao, H., Li, G., Yi, Y., & Shang, R. (2024). Design and synthesis of pleuromutilin derivatives as antibacterial agents using quantitative structure–activity relationship model. International Journal of Molecular Sciences, 25(4), 2256. https://doi.org/10.3390/ijms25042256
  • Abuelizz, H. A., Marzouk, M., Ghabbour, H., & Al-Salahi, R. (2017). Synthesis and anticancer activity of new quinazoline derivatives. Saudi Pharmaceutical Journal, 25(7), 1047–1054.